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Background
Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) 
are undefined. The relationships between patterns of mutations and epigenetic 
phenotypes are not yet clear.
Methods
We analyzed the genomes of 200 clinically annotated adult cases of de novo AML, 
using either whole-genome sequencing (50 cases) or whole-exome sequencing (150 
cases), along with RNA and microRNA sequencing and DNA-methylation analysis.
Results
AML genomes have fewer mutations than most other adult cancers, with an average 
of only 13 mutations found in genes. Of these, an average of 5 are in genes that are 
recurrently mutated in AML. A total of 23 genes were significantly mutated, and 
another 237 were mutated in two or more samples. Nearly all samples had at least 
1 nonsynonymous mutation in one of nine categories of genes that are almost cer-
tainly relevant for pathogenesis, including transcription-factor fusions (18% of 
cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes 
(16%), DNA-methylation–related genes (44%), signaling genes (59%), chromatin-
modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex 
genes (13%), and spliceosome-complex genes (14%). Patterns of cooperation and 
mutual exclusivity suggested strong biologic relationships among several of the 
genes and categories.
Conclusions
We identified at least one potential driver mutation in nearly all AML samples and 
found that a complex interplay of genetic events contributes to AML pathogenesis 
in individual patients. The databases from this study are widely available to serve 
as a foundation for further investigations of AML pathogenesis, classification, and 
risk stratification. (Funded by the National Institutes of Health.)
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The molecular pathogenesis of acute myeloid leukemia (AML) has been studied with the use of cytogenetic analysis for 
more than three decades. Recurrent chromosom-
al structural variations are well established as 
diagnostic and prognostic markers, suggesting 
that acquired genetic abnormalities (i.e., somatic 
mutations) have an essential role in pathogene-
sis.1,2 However, nearly 50% of AML samples have 
a normal karyotype, and many of these genomes 
lack structural abnormalities, even when as-
sessed with high-density comparative genomic 
hybridization or single-nucleotide polymorphism 
(SNP) arrays3-5 (see Glossary). Targeted sequenc-
ing has iden tified recurrent mutations in FLT3, 
NPM1, KIT, CEBPA, and TET2.6-8 Massively parallel 
sequencing enabled the discovery of recurrent 
mutations in DNMT3A9,10 and IDH1.11 Recent 
studies have shown that many patients with AML 
carry no mutations in any of the currently recog-
nized driver genes associated with the pathogen-
esis of AML.8,12
Patients with a cytogenetic profile that is associ-
ated with a favorable risk (i.e., those with PML-
RARA, RUNX1-RUNX1T1, or MYH11-CBFB fusions) 
have relatively good outcomes with chemotherapy-
based consolidation regimens, whereas patients 
with an unfavorable-risk profile (monosomy karyo-
type or complex alterations) require allogeneic 
transplantation during the first remission to im-
prove their prognosis.13,14 However, the majority 
of patients with AML have an intermediate cyto-
genetic risk (most commonly, a normal karyo-
type); some of these patients do well with che-
motherapeutic consolidation, but others have a 
very poor outcome. For this reason, recent stud-
ies have focused on establishing new biomarkers 
for better classification of intermediate risk.8,15,16 
Newer classification algorithms incorporate FLT3, 
NPM1, CEBPA, and KIT into standard-of-care test-
ing. Even more recently, testing has revealed that 
mutations in newly discovered AML genes (e.g., 
DNMT3A, IDH1/2, and TET2) may also provide 
prognostic information for some patients with 
an intermediate-risk profile.8,12,16 None of the 
current classification schemes are entirely accu-
rate, which suggests that a more complete un-
derstanding of the genetic and epigenetic chang-
es that are relevant to the pathogenesis of AML 
will be required for better classification of risk 
and, ultimately, better approaches to therapy.
Me thods
Patients
We selected samples from 200 adults with de 
novo AML to represent the major morphologic 
and cytogenetic subtypes of AML.8,15,16 The char-
acteristics of these patients are fully described in 
Table 1, and in Tables S1 and S2, Figure S1, and 
Glossary
Comparative genomic hybridization: An array-based method that permits comparison of DNA abundance throughout 
the genome between two DNA samples to identify regions where DNA copies have been gained or lost.
DNA methylation: This generally refers to the addition of a methyl group to the 5-carbon of the pyrimidine ring of cyto-
sine, usually pertaining to cytosines that precede a guanine residue in DNA (a CpG dinucleotide motif). DNA meth-
ylation of CpG-rich regions (CpG islands) is often associated with repression of nearby genes.
MicroRNA: A short regulatory form of RNA that binds to a target RNA and suppresses its translation or alters its stability.
Single-nucleotide polymorphism (SNP) array: A microarray-based assay system that allows for simultaneous measure-
ment of nucleotide sequence of hundreds of thousands of SNPs throughout the genome in a DNA sample. Acquired 
copy-number variants can sometimes be detected with SNP arrays by comparing signals from the tumor and nor-
mal samples obtained from the same individual.
Single-nucleotide variant (SNV): A difference in a DNA sequence at a single position in the genome, as compared with 
the reference genome; each variant may represent either an inherited or an acquired (somatic) change. SNPs gener-
ally represent inherited changes only.
Variant-allele clusters: Groups of mutations with similar variant allele frequencies, defined by statistical approaches. 
A large group of mutations with variant-allele frequencies of approximately 50% generally represents the founding 
clone of that tumor.
Variant-allele frequency (VAF): The relative proportion of sequencing reads from a variant allele (i.e., somatic mutation) 
in a tumor sample. The VAF can be used to estimate the fraction of cells within a sample that contain that variant. 
For example, variant alleles with a VAF of 50% usually represent heterozygous somatic mutations that are present 
in all cells within the sample. Variant alleles with lower VAFs are generally present in only a fraction of the cells in a 
sample, which may represent subclones derived from the founding clone of a tumor.
Whole-exome sequencing: Sequencing of the coding regions, or exons, of an entire genome from a single individual.
Whole-genome sequencing: Determination of the primary nucleotide sequence of the entire genome from a single individual.
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the Materials section in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org. A video describing AML and this 
study is also available at NEJM.org.
Analytic Platforms
We performed whole-genome sequencing of the 
primary tumor and matched normal skin sam-
ples from 50 patients (with data from 24 of these 
patients reported previously17) and exome cap-
ture and sequencing for another 150 paired sam-
ples of AML tumor and skin (see Table S3 in the 
Supplementary Appendix for coverage data for the 
200 samples).
All 200 patients who were selected for this 
study were enrolled in a single-institution tissue-
banking protocol approved by the human stud-
ies committee at Washington University. Written 
informed consent for whole-genome sequencing 
was obtained from all study participants.
The samples, which were banked between No-
vember 2001 and March 2010, were selected from 
a set of more than 400 samples to reflect a real-
world distribution of subtypes. Sample inventory 
and quality issues also had to be considered in 
the selection process, since the samples were ana-
lyzed on several different platforms. We identi-
fied candidate somatic variants using several al-
gorithms (see the Methods section in the 
Supplementary Appendix), and all the variants for 
the 200 samples were verified with the use of 
hybridization capture–based methods and deep 
digital sequencing.18 We performed RNA-expres-
sion profiling on the Affymetrix U133 Plus 2 
platform for 197 samples, RNA sequencing for 
179 samples, microRNA (miRNA) sequencing for 
194 samples, Illumina Infinium HumanMethyl-
ation450 BeadChip profiling for 192 samples, 
and Affymetrix SNP Array 6.0 for both tumor and 
normal skin samples from all 200 patients. Data 
sets were not completed for all samples on all 
platforms because of assay failures and availabil-
ity and quality issues for some samples. The com-
plete list of data sets is provided in Table S4 in 
the Supplementary Appendix. All data sets are 
available through the Cancer Genome Atlas (TCGA) 
data portal (https://tcga-data.nci.nih.gov/tcga).
R esult s
Copy-Number Alterations
In most de novo AML samples with a cytogenetic 
profile indicating intermediate or favorable risk, 
we detected very few copy-number events on high-
resolution SNP arrays, as reported previously3 
(Fig. S2 and Table S5 in the Supplementary Ap-
pendix). Unfavorable-risk samples had chromo-
somal copy-number alterations that were verified 
on the SNP arrays, and many had additional, cyto-
genetically cryptic events. No samples contained 
evidence of chromothripsis (a single genomic event 
that results in focal losses and rearrangements in 
multiple genomic regions).19 Details of these anal-
yses are presented in the Materials section in the 
Supplementary Appendix.
Mutations in Coding Sequences
We discovered 2315 somatic single-nucleotide vari-
ants (SNVs) and 270 small insertions and deletions 
(indels) in coding (tier 1) regions of the genome, 
with an average of 13 tier 1 mutations per sample 
(range, 0 to 51) (see box, and Table S6 in the 
Supplementary Appendix). We observed no re-
curring coding mutations in three samples, but 
all contained well-recognized fusion events that 
are known to initiate AML (NUP98-NSD1 in Patient 
868231, MLL-MLLT3/AF9 in Patient 923966, and 
MLL-MLLT10/AF10 in Patient 558395). Three out-
lier samples contained 51, 36, and 35 tier 1 muta-
tions; none of these samples contained mutations 
in known DNA-repair genes. Of the 2315 SNVs, 
1539 (66%) were missense and 510 (22%) had no 
translational consequences. Small indels ac-
counted for 270 of the 2585 validated mutations 
(10%); of these, 191 (71%) caused frameshifts.
Samples were stratified into 10 groups on the 
Tiers of Variants
Somatic variants that are identified on whole-genome sequencing and other large-scale sequencing analyses are often cate-
gorized according to their likely effect on biologic function. In this study, the somatic variants were divided into four tiers.
Tier 1: Changes in the amino acid coding regions of annotated exons, consensus splice-site regions, and RNA genes 
(including microRNAs).
Tier 2: Changes in highly conserved regions of the genome or regions with regulatory potential.
Tier 3: Changes in the nonrepetitive part of the genome that do not meet the criteria for tier 2.
Tier 4: Changes in the remainder of the genome.
A video detailing 
the findings of 
this study is 
available at 
NEJM.org 
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basis of the presence or absence of known recur-
ring fusion events, cytogenetic-risk profile, or the 
presence or absence of TP53 mutations (which were 
strongly associated with an unfavorable cytoge-
netic risk) (Fig. 1A). We observed significant dif-
ferences in the numbers of recurrent tier 1 muta-
tions in some of these groups. Eleven samples 
had MLL fusions; this group had the fewest re-
current tier 1 mutations, with a mean of 2.09, as 
compared with a mean of 5.24 for all 200 sam-
ples (P = 0.002 after correction for multiple com-
parisons). This finding suggests that MLL fusions 
require fewer cooperating mutations than other 
AML-initiating events. Similarly, 20 samples con-
taining PML-RARA fusions had fewer recurrent 
tier 1 mutations (mean, 3.25; P = 0.001). We ob-
served a higher mean number of recurrent tier 1 
mutations in 7 samples containing either RUNX1-
RUNX1T1 fusions (mean value, 7.85; P = 0.04) and 
in 13 samples with a combination of a high-risk 
cytogenetic profile and a TP53 mutation (mean, 
7.00; P = 0.049). Larger sample sets will be re-
quired to confirm these observations.
A total of 260 genes had somatic mutations in 
at least 2 of the 200 samples; in 154 of these 
genes, more than one mutation was nonsynony-
Table 1. Characteristics of the 200 Patients.*
Characteristic Value
Age at study entry — yr 55.0±16.1
Race or ethnic group — no. (%)†
White 178 (89)
Black 15 (8)
Other 7 (4)
Male sex — no. (%) 108 (54)
Bone marrow blasts at diagnosis — % 69.3±19.1
Normal cytogenetic profile — no./total no. (%) 92/195 (47)
White-cell count at diagnosis — per mm3
Mean 36,300±48,500
Median 16,200
Cytogenetic risk group — no. (%)
Favorable 37 (18)
Intermediate 115 (58)
Unfavorable 43 (22)
Missing data 5 (2)
AML FAB subtype — no. (%)
AML with minimal maturation: M0 19 (10)
AML without maturation: M1 46 (23)
AML with maturation: M2 44 (22)
Acute promyelocytic leukemia: M3 20 (10)
Acute myelomonocytic leukemia: M4 41 (20)
Acute monoblastic or monocytic leukemia: M5 22 (11)
Acute erythroid leukemia: M6 3 (2)
Acute megakaryoblastic leukemia: M7 3 (2)
Other subtype 2 (1)
Immunophenotype — no./total no. (%)
CD13+ 140/185 (76)
CD33+ 160/198 (81)
CD34+ 123/199 (62)
CD117+ 174/185 (94)
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mous. An additional 1623 genes were found to 
have a validated tier 1 mutation in one sample. 
Using the significantly mutated gene (SMG) test 
in the Mutational Significance in Cancer (MuSiC) 
suite of tools,20 we identified 23 genes with a 
higher-than-expected mutation prevalence (false 
discovery rate, <0.05), including genes that are 
well established as being relevant to AML patho-
genesis (e.g., DNMT3A, FLT3, NPM1, IDH1, IDH2, 
and CEBPA), along with genes that have only re-
cently been implicated in AML pathogenesis, in-
cluding U2AF1, EZH2, SMC1A, and SMC3 (Fig. 1B, 
and Table S7 in the Supplementary Appendix).
We also identified and verified all variants in 
noncoding regions in the 50 sample pairs that we 
analyzed using whole-genome sequencing. After 
the exclusion of 1 tumor sample, from Patient 
817156, that had a high level of AML tumor cells 
(36%) in the skin sample (Table S1 in the Supple-
mentary Appendix), the median number of non-
coding mutations in tumor samples was 394, 
ranging from 68 to 1298. There was a strong 
correlation between the number of coding and 
noncoding mutations in each genome (Pearson’s 
correlation coefficient, 0.78), suggesting that most 
of the mutations were randomly distributed 
throughout each genome. Most mutations in AML 
genomes are probably background events that 
occurred in hematopoietic stem cells before the 
initiating event occurred; the clonal expansion 
of these cells captures their mutational history, 
as reportedly previously.17 This is also the reason 
why nearly all mutations in AML genomes are 
present in nearly all the cells in each sample.17 
The results of an analysis of recurrently mutated 
regions in tiers 2 and 3 (nongenic regions11) are 
presented in Table S8 in the Supplementary Ap-
pendix, as are data for mitochondrial variants 
(Table S9 in the Supplementary Appendix); the 
relevance of these events to pathogenesis is un-
clear.
Using deep digital sequencing, we verified all 
tier 2 and 3 variants that were discovered with the 
use of whole-genome sequencing. This provided a 
large number of sites for variant allele frequency 
(VAF)–based cluster analysis, which allowed us to 
Table 1. (Continued.)
Characteristic Value
Mutation — no./total no. (%)
NPM1 54/200 (27)
FLT3 56/200 (28)
DNMT3A 51/200 (26)
IDH1 or IDH2 39/200 (20)
NRAS or KRAS 23/200 (12)
RUNX1 19/200 (10)
TET2 17/200 (8)
TP53 16/200 (8)
CEBPA 13/200 (6)
WT1 12/200 (6)
PTPN11 9/200 (4)
KIT 8/200 (4)
Loss of 5 or del(5q) 16/195 (8)
Loss of 7 or del(7q) 20/195 (10)
11q23 7/195 (4)
t(15;17) 18/195 (9)
t(8;21) 7/195 (4)
inv(16) 12/195 (6)
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. AML denotes acute myeloid 
leukemia, and FAB French–American–British classification.
† Race or ethnic group was self-reported.
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define the clonal composition of each tumor.17,18 
More than half the tumors contained both a 
founding clone (the clone with the highest VAF 
values) and at least one subclone; we were able to 
identify as many as three independent subclones 
in one tumor sample (Fig. 1C, and Table S1 in the 
Supplementary Appendix). The coverage provided 
by whole-genome sequencing in this study (mean, 
30.54×) limited the power to detect small sub-
clones with VAFs of less than 10% (Fig. S3A in 
the Supplementary Appendix). Exome sequencing 
produced a higher level of coverage for the tar-
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Figure 1. Characterization of Mutations.
Panel A shows the numbers of verified, recurrent tier 1 mutations in each of 200 samples obtained from patients with AML, organized 
according to important cytogenetic and mutational findings. For each set of data, the middle horizontal line indicates the mean, and the 
shaded area indicates ±1 SD. P values are shown for the groups that had significant differences from the mean number of recurrent tier 1 
mutations in all samples. NK denotes normal karyotype. Panel B shows significantly mutated genes, as identified by the MuSiC analysis 
suite,20 and the number of samples with each mutation. Panel C shows the number of discrete clusters of mutations with distinct variant 
allele frequencies (VAFs) for each of 50 samples that underwent whole-genome sequencing. Each discrete VAF cluster represents a found-
ing clone or a subclone derived from it.17,18 Samples with one clone have only a founding clone, those with two clones have a founding 
clone and one subclone, those with three clones have a founding clone and two subclones, and so forth. Exome sequencing defined too 
few mutations to accurately define subclones. Each sample contained evidence of a single founding clone, and most had one or more 
subclones derived from the founding clone. The French–American–British (FAB) subtypes of the samples are designated. (See Table 1 
for FAB subtypes of AML.)
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geted sequences (mean, 167.50×), slightly increas-
ing our ability to detect mutations with VAFs of 
less than 10%. However, the difference between 
the number of tier 1 mutations detected with 
whole-genome sequencing (14.5 per sample) and 
the number detected with exome sequencing 
(12.7 per sample) was not significant (P = 0.17) 
(Table S6 in the Supplementary Appendix). The 
mutational spectrum of all validated SNVs for all 
200 samples is shown in Figure S3B in the Supple-
mentary Appendix; transitions were the most com-
mon mutation type, as reported previously.17,18
Expression of Mutant Alleles
Analysis of RNA sequences revealed allelic bias for 
mutations in several genes. We observed increased 
or exclusive expression of the mutant DNMT3A, 
RUNX1, PHF6, and TP53 in several cases (Fig. S4A 
through S4F in the Supplementary Appendix). 
Loss of heterozygosity or partial uniparental di-
somy explained the enrichment of mutant allele 
expression in most samples; epigenetic modifi-
cations (e.g., altered patterns of DNA or histone 
meth yl a tion) may be responsible for the rest.
MiRNA Variants
We identified somatic SNVs in miRNA genes in 
7 of 200 samples (4%) (Table S10 in the Supple-
mentary Appendix). Of these 7 samples, 4 had 
mutations in miR-142 that were localized to the 
seed region of the mature strand (a sequence from 
the 3′ region called miR-142-3p) and were likely 
to affect messenger RNA (mRNA) target specific-
ity (Fig. S5A in the Supplementary Appendix). The 
expression of miR-142-3p and miR-142-5p (a se-
quence from the 5′ region) is thought to be re-
stricted primarily to the hematopoietic compart-
ment.21,22 Data from miRNA sequencing showed 
that miR-142 was highly expressed in AML sam-
ples (Fig. S5B in the Supplementary Appendix). 
The mutated miR-142 alleles were expressed at lev-
els similar to those of the nonmutated allele in 
all samples (Fig. S5C in the Supplementary Ap-
pendix). Although miR-142 mutations have not 
previously been identified, several reports have 
linked aberrant expression of miR-142-3p with 
hematologic cancers, including precursor B-cell23 
and T-cell24,25 acute lymphoblastic leukemia and 
AML.26 The remaining mutations in miRNA 
genes were localized to precursor miRNAs (in 
3 samples) or to a nonseed region of a mature 
miRNA (in 1 sample).
Germline Variants
We identified all the variants predicted to cause 
mRNA truncation that were found in both the 
skin and tumor samples (see the Results section, 
Table S11, and Fig. S6 in the Supplementary Ap-
pendix). However, very few of the genes with 
truncation variants were found to be expressed 
in most AML samples (including the samples car-
rying the variants themselves), suggesting that 
most of the inherited truncating variants were 
probably irrelevant for pathogenesis.
Functional Categorization of Mutated Genes
We used complementary approaches to identify 
combinations of mutations in the samples; for 
this analysis, we considered only nonsynony-
mous mutations (Fig. 2). Using the HotNet algo-
rithm,27 we identified six subnetworks of a ge-
nome-scale protein–protein interaction network 
that had significant mutations (P<0.001). These 
included portions of known pathways and pro-
tein complexes, including the cohesin complex17 
(Fig. S7 in the Supplementary Appendix).
We grouped mutations into larger sets or path-
ways and examined patterns of mutual exclusiv-
ity and co-occurrence between these groups. Of 
200 samples, 199 (>99%) contained at least one 
mutation in one of nine categories that were 
defined according to biologic function and that 
have a putative role in AML pathogenesis: tran-
scription-factor fusions (18% of cases), the gene 
encoding nucleophosmin (NPM1) (27%), tumor-
suppressor genes (16%), DNA-methylation–related 
genes (44%), activated signaling genes (59%), 
chromatin-modifying genes (30%), myeloid tran-
scription-factor genes (22%), cohesin-complex 
genes (13%), and spliceosome-complex genes (14%) 
(Fig. 2, and Fig. S8 in the Supplementary Appen-
dix). For all genes that had mutations in only a 
small number of samples, the pathophysiological 
relevance of the events will require further valida-
tion. FLT3 mutations were identified in 56 sam-
ples, and an additional 62 samples were found 
to have mutations in genes encoding other ki-
nases, phosphatases, or RAS family proteins 
(Fig. S9 in the Supplementary Appendix). How-
ever, most of these genes contained mutations 
in only 1 to 3 samples (with the exception of KIT, 
KRAS, NRAS, and PTPN11). In total, 59% of sam-
ples had a mutation in a gene encoding a signal-
ing protein.
To more fully assess patterns of mutual exclu-
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sivity and co-occurrence between sets of genes, 
we applied Dendrix++ (see the Materials section 
in the Supplementary Appendix) to the mutation 
matrix. Dendrix++ identified three sets of genes 
with the strongest patterns of mutual exclusivity 
(groups A, B, and C) (Fig. 2). The most statisti-
cally significant set included the transcription-
factor fusion genes, NPM1, RUNX1, TP53, and 
CEBPA (Fig. S10 in the Supplementary Appendix). 
The second most significant set showed exclusiv-
ity between mutations in FLT3 and in genes en-
coding other tyrosine kinases, serine–threonine 
kinases, protein tyrosine phosphatases, and RAS 
family proteins (Fig. S9 in the Supplementary 
Appendix). The third set included mutations in 
ASXL1 and in genes encoding components of the 
cohesin complex, other myeloid transcription fac-
tors, and other epigenetic modifiers (Fig. S10 in 
the Supplementary Appendix). Mutations within 
the spliceosome gene set, genes encoding other 
epigenetic modifiers, and genes encoding myeloid 
transcription factors also showed considerable 
mutual exclusivity within each set (Fig. S11 in the 
Supplementary Appendix).
Among the pairwise relationships between mu-
tations in the AML samples, the most prominent 
was the significant co-occurrence between muta-
tions in FLT3, DNMT3A, and NPM1 (Fig. S8 in the 
Supplementary Appendix). In particular, many 
samples had mutations both in NPM1 and 
 DNMT3A or in NPM1 and FLT3. The likelihood 
that these mutations occurred together by chance 
is extremely small (P<6.3×10−7 for NPM1 and 
 DNMT3A and P<1.9×10−6 for NPM1 and FLT3). 
This observation, combined with the strong as-
sociation between samples having concurrent 
mutations in NPM1, FLT3, and DNMT3A and dis-
tinct clusters in mRNA, miRNA, and DNA 
methylation, suggests that samples with muta-
tions in all three genes represent a novel subtype 
of AML. Furthermore, we observed relationships 
of strong mutual exclusivity. For example, PML-
RARA, MYH11-CBFB, and MLL-containing fusion 
genes were mutually exclusive of mutations in 
NPM1 and DNMT3A (P<0.007, P<0.04, and P<0.04, 
respectively), and RUNX1 and TP53 mutations were 
mutually exclusive of FLT3 and NPM1 mutations. 
Table S12 in the Supplementary Appendix contains 
a full list of genes or gene sets with significant 
co-occurrences or exclusivity among the samples.
Gene Fusions
De novo assembly of RNA-sequencing data28 for 
179 AML samples identified 118 gene fusions 
in 80 samples (mean, 1.5 per sample), of which 
71 were distinct events (Fig. 3A)29; 99 samples 
had no detected fusions (Table S13 in the Supple-
mentary Appendix). The range of fusions per sam-
ple was 0 to 8. The 74 in-frame fusions included 
many previously described, recurrent events, in-
cluding PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1, 
BCR-ABL1, PICALM-MLLT10/AF10, NUP98-NSD1, and 
multiple fusions involving MLL (Fig. 3B). We iden-
tified 15 new fusion events that maintained an 
open reading frame. Although none of them were 
recurrent in this cohort, several of the genes in 
the fusions were mutated or translocated in other 
samples of AML that we analyzed (i.e., MLLT10/
AF10, NF1, GRID1, PPP2R1B, XIAP, ATP1B4, WSB1, 
KIAA0999, TBX15, and LRRC37B). An additional 
42 gene fusions were out-of-frame (Fig. 3C), cre-
ating a truncated upstream gene or potential 
haploinsufficiency for both partner genes, with 
many that were mutated or translocated in other 
AML samples (including RUNX1, DNMT3B, MLLT10/
AF10, NSD1, EDIL3, SCARB1, XIAP1, PPP2R1B, FOXP1, 
KSR2, MLL3, and CUL1). One out-of-frame fusion 
(GAS6-FAM70B) was detected in three AML sam-
ples, and one of its fusion partners (FAM70B 
P233L) was mutated in another sample. Most of 
the newly described fusion events in these sam-
ples were not detected by means of routine cyto-
genetic studies (Table S1 in the Supplementary 
Appendix).
Figure 2 (facing page). Organization of Mutations 
into Categories of Related Genes.
Shown are somatic, nonsynonymous mutations in in-
dividual genes and sets of genes, grouped into nine 
categories, including one single-gene category, as la-
beled on the left. Of the 200 samples evaluated, 199 
(>99%) had at least one mutation in one of the listed 
genes or sets. Blue boxes indicate mutations that are 
exclusive across all categories; green boxes, mutations 
that co-occur in the same sample across different cate-
gories; and orange boxes, mutations that co-occur in 
the same sample in the same category. Computational 
analysis with the use of the Dendrix++ algorithm iden-
tified three significant, mutually exclusive groups of 
genes, annotated on the right as groups A, B, and C. 
The cytogenetic risk for each patient is shown at the 
bottom of the chart. Additional information about data 
in this figure is provided in Tables S17 through S20 in 
the Supplementary Appendix. Ser–Thr denotes serine–
threonine, TF transcription factor, and Tyr tyrosine.
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Figure 3. AML Gene Fusions.
Panel A is a plot created with the use of Circos software29 showing in-frame (green) and out-of-frame (orange) gene fusions 
detected in the AML cohort in the Cancer Genome Atlas (TCGA) with the use of Trans-ABySS software.28 Ribbon widths 
are proportional to the frequency of a fusion event. Chromosomes are individually colored and are arranged clockwise 
from chromosome 1 to X, starting with chromosome 1 at 12 o’clock. No rearrangements involved the Y chromosome. The 
frequencies of in-frame and out-of-frame gene fusions are shown in Panels B and C, respectively. For gene names shown 
in red, one of the partner genes in that fusion was found to be mutated in at least one other AML sample from this data 
set. On the basis of chromosomal aberrations and genomic variants annotated in the Mitelman database from the Cancer 
Genome Anatomy Project (CGAP) (http://cgap.nci.nih.gov/Chromosomes/Mitelman), all previously identified gene fu-
sions are shown in blue, a single known polymorphic fusion is shown in green, and all novel events are shown in red.
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Gene-Expression Analysis
Unsupervised non-negative matrix factorization 
(NMF) consensus clustering (i.e., clustering data 
with inputs consisting only of gene or miRNA 
abundance information) suggested an optimum of 
seven RNA-sequencing groups and five miRNA-
sequencing groups (Fig. S12 in the Supplementary 
Appendix). Associations between these groups 
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Figure 4. Unsupervised RNA and miRNA Expression Patterns.
Shown are unsupervised consensus clusters for data obtained with the use of messenger RNA sequencing (Panel A) and microRNA 
(miRNA) sequencing (Panel B). Shown from top to bottom are RNA abundance heatmaps, with each messenger RNA or miRNA cen-
tered on its mean; atypical members of each group (shown in black), which have silhouette widths below 0.9 of the group’s maximum 
width; a silhouette-width profile (i.e., a dimensionless metric that reflects how well samples fit into compact and distinct clusters) that 
was calculated from the consensus membership matrix; and covariates (e.g., FAB subtypes), with P values for association corrected for 
multiple testing, at the far left and far right (see the Methods section in the Supplementary Appendix). B-H denotes Benjamini–Hochberg 
multiple-testing correction. The numbers refer to the silhouette-width profiles for which P values are provided. One asterisk denotes 
P<0.05, two asterisks P<0.01, and three asterisks P<0.001. The color scales for both heatmaps reflect mean-normalized log2 abundances, 
with RPKM (reads per kilobase of exon model per million mapped reads) for RNA-sequencing data and log
2
 RPM (reads per million) for 
miRNA-sequencing data. The scale-bar numbers (−2.5 for least abundant to 2.5 for most abundant) indicate the range of log2 mean-cen-
tered abundance values in the heatmaps. Cytogenetic-risk profiles are shown at the bottom of the chart.
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and overall survival are shown in Fig. S13 in the 
Supplementary Appendix; the groups enriched 
for samples containing PML-RARA had better 
outcomes than other groups, as expected. The 
RNA-sequencing groups were highly concordant 
with a microarray data set for the same 178 sam-
ples (Fig. S14 in the Supplementary Appendix).
We used one-sided Fisher’s exact tests (cor-
rected for multiple testing) to identify significant 
associations (P<0.05) between specific RNA- 
sequencing and miRNA-sequencing groups and 
covariates (Fig. 4). RNA-sequencing group 4 was 
associated with subtype M1 (AML with minimal 
maturation) in the French–American–British (FAB) 
classification of acute leukemias, group 3 with 
FAB subtype M3 (acute promyelocytic leukemia), 
group 5 with FAB subtype M4 (acute myelomono-
cytic leukemia), and group 7 with FAB subtype 
M5 (acute monoblastic or monocytic leukemia) 
(Fig. 4A). Concordance between gene-expression 
groups and FAB subtypes was similar to that 
previously reported for microarray data30,31 and 
showed that some expression signatures were 
strongly correlated with the stage of myeloid dif-
ferentiation of the AML sample.
For the miRNA-sequencing data, group 5 was 
associated with FAB subtype M3, and groups 2, 
3, and 5 were associated with unfavorable, inter-
mediate, and favorable cytogenetic risk categories, 
respectively. Group 3 was strongly associated with 
mutations in NPM1, DNMT3A, FLT3, and genes 
encoding the cohesin complex; miR-10a was ex-
pressed at high levels in this group, an observa-
tion that is consistent with reports correlating high 
miR-10a expression and NPM1 mutations32,33 
(Fig. 4B). Levels of miR-424 were relatively low 
in this group, making miR-424 the second-most 
discriminatory miRNA — an observation that is 
consistent with the findings in a previous study.34 
The data also confirmed that miR-196b, miR-130a, 
and let-7b were discriminatory in this group.35 
Additional comparisons with published sets of 
expression data are provided in the Materials 
section in the Supplementary Appendix.
DNA-Methylation Analysis
Unsupervised analysis of changes in DNA meth-
ylation revealed significant differences among sub-
sets of samples, particularly in CpG-sparse re-
gions of the genome (Fig. 5).36 Samples with 
IDH1 and IDH2 mutations showed extensive gains 
of methylation relative to CD34+CD38− cells ob-
tained from healthy donors (Table S14 in the 
Supplementary Appendix), whereas some samples 
with MLL fusions or co-occurring NPM1, DNMT3A, 
and FLT3 mutations were associated with exten-
sive loss of DNA methylation, as compared with 
normal CD34+CD38− cells. Specific patterns of 
methylation gain and loss distinguished samples 
with CEBPA mutations, as well as samples with 
PML-RARA, RUNX1-RUNX1T1, or MYH11-CBFB fu-
sions. Significant changes in DNA methylation 
were identified across AML samples at 160,519 
CpG loci (42% of sites tested), with 67% result-
ing in a gain of methylation and 33% resulting in 
a loss (see the Methods section and Table S15 in 
the Supplementary Appendix). Samples with 
triple mutations in NPM1, DNMT3A, and FLT3 
showed methylation losses at 328 of 382 differ-
entially methylated regions larger than 1 kb 
(86%), as compared with CD34+CD38− cells 
from healthy donors. Although both intergenic 
and genic regions were affected, approximately 
71% of these changes were in coding regions 
(Table S16 in the Supplementary Appendix).
We also assessed the relationships between 
gene expression and DNA methylation in pairs 
of data types by identifying groups in one data 
type that were enriched in samples from a group 
in the other data type (Fig. S15A through S15E in 
the Supplementary Appendix). Clusters contain-
ing samples of acute promyelocytic leukemia were 
strongly concordant for mRNA, miRNA, and 
CpG-sparse DNA methylation (Fig. 5, and Fig. 
Figure 5 (facing page). Unsupervised Analysis of DNA 
Methylation at Extremes of CpG Density.
DNA-methylation values for specific CpG residues are 
shown as a proportion, ranging from 0% (unmethylated, 
in blue) to 100% (fully methylated, in red), for unsuper-
vised clustering of CpG-dense regions of the genome 
(Panel A) and of CpG-sparse regions (Panel B). Covari-
ates are shown below the corresponding samples. Data 
for CD34+CD38− bone marrow cells, promyelocytes, 
neutrophils, and monocytes from three healthy volun-
teers are plotted to the left of the data for 192 AML 
samples in each panel. CpG islands and shores are an-
notated in dark green and light green, respectively, in 
the space between the normal and AML samples. CpG 
density was computed as the ratio of observed to expect-
ed CG dinucleotides in a 3-kb window, as described by 
Saxonov et al.36 The 1000 most variable loci among 
those falling into the top and bottom 5% according to 
CpG density are plotted in Panels A and B, respectively. 
Cytogenetic-risk profiles are shown at the bottom of 
the chart.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;22 nejm.org may 30, 20132072
S15 in the Supplementary Appendix). In mRNA 
groups 1, 2, 5, and 6, there was a preferential 
association with one miRNA-sequencing group 
each, suggesting that regulatory relationships must 
exist between these groups (Fig. S15A in the 
Supplementary Appendix). Associations in CpG-
sparse DNA methylation groups were more sig-
nificant for miRNA groups than for mRNA 
groups, suggesting the existence of previously 
unrecognized epigenetic regulatory pathways (Fig. 
S15B through S15E in the Supplementary Ap-
pendix). Genes defining the RNA- and miRNA-
sequencing groups are shown in Figure S16 in 
the Supplementary Appendix; a very striking set 
of small RNA genes within an imprinted locus on 
chromosome 14 were found to be consistently 
dysregulated in acute promyelocytic leukemia 
(Fig. S17 in the Supplementary Appendix).37
Discussion
Of the adult cancer types that have been exten-
sively sequenced to date, AML has had the fewest 
mutations discovered (Fig. S18 in the Supplemen-
tary Appendix). The average number of coding 
mutations (SNVs and indels) per patient in this 
study was 13, of which only 5 were recurrently 
mutated in each genome. There was little evi-
dence of genomic instability in most AML ge-
nomes. However, a small number of patients had 
an unfavorable-risk (complex) cytogenetic profile 
that was strongly associated with mutations in 
TP53, which confirmed a recently reported rela-
tionship.38 Adult AML genomes contain a medi-
an of only one somatic copy-number variant and an 
average of less than one gene-fusion event (gener-
ally caused by translocations).1,2
The organization of mutated genes into nine 
functionally related categories revealed many 
potentially important biologic relationships. The 
transcription-factor fusions were the first recog-
nized somatic mutations in AML genomes,1,2 and 
all such fusions have been shown to be relevant 
for disease initiation in mice.39-42 Our data show 
that some mutations that are common in AML 
(e.g., in DNMT3A, NPM1, CEPBA, IDH1/2, and RUNX1) 
are mutually exclusive of the transcription-factor 
fusions, suggesting that these mutations may have 
functions in the initiation of AML that are similar 
to the functions of fusion genes. We also identi-
fied a pattern of mutual exclusivity for mutations 
in genes within certain biologic classes, including 
those encoding the cohesins, proteins of the splice-
osome, signaling proteins, and histone-modifying 
proteins, suggesting that one mutation in these 
pathways is generally adequate for AML pathogen-
esis. Although a common model of AML patho-
genesis has suggested that an activating muta-
tion in a gene encoding a signaling protein might 
be a requirement for pathogenesis,43 only 59% of 
the patients in our study had a mutation in a 
gene annotated to suggest a role in signaling.
We integrated the expression data for both 
mRNA and miRNA with all the clinical and mu-
tational data for all genomes. That analysis re-
vealed that the differentiation state of the AML 
sample was highly correlated with the expres-
sion signature, as reported previously.44 Patients 
who had PML-RARA fusions had very distinct 
mRNA and miRNA signatures that were strongly 
correlated with each other and with a specific DNA 
methylation signature.45 All the transcription-
factor fusions were correlated with specific pat-
terns of mRNA expression, whereas PML-RARA 
and RUNX1-RUNX1T1 (and some MLL fusions) were 
also associated with miRNA expression signatures. 
In addition, occurrence of NPM1, DNMT3A, and 
FLT3 mutations together was strongly associated 
with specific expression signatures for both 
mRNA and miRNA. These data suggest that this 
combination of mutations in patients with inter-
mediate-risk AML may identify a subtype of AML 
with unique epigenetic features. Our analysis of 
methylation patterns corroborates previous re-
ports of methylation signatures in CpG islands for 
transcription-factor fusions and IDH1/2 muta-
tions46,47 but surprisingly revealed that the stron-
gest methylation signatures occur in CpG-sparse 
regions of the genome. Although the signifi-
cance of this finding is not yet clear, the wide-
spread and variable losses of methylation in 
these regions are consistent with observations 
from analyses of epithelial tumors48 and support 
the idea that methylation patterns in gene bod-
ies and intergenic regions are important for the 
regulation of gene expression.49
This data set will be available to provide a 
framework for future studies that pertain to the 
molecular classification of patients with AML. 
The identification of many potentially important 
relationships among recurrently mutated AML 
genes and pathways provides a comprehensive 
foundation for an understanding of the genetic 
rules of pathogenesis.
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